

Accepted Manuscript

Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus

Mehmet Burcu, PhD, MS, Julie M. Zito, PhD, Daniel J. Safer, MD, Laurence S. Magder, PhD, Susan dosReis, PhD, Fadia T. Shaya, PhD, MPH, Geoffrey L. Rosenthal, MD, PhD

PII: S0890-8567(17)30201-0

DOI: [10.1016/j.jaac.2017.04.004](https://doi.org/10.1016/j.jaac.2017.04.004)

Reference: JAAC 1749

To appear in: *Journal of the American Academy of Child & Adolescent Psychiatry*


Received Date: 28 January 2017

Revised Date: 15 April 2017

Accepted Date: 26 April 2017

Please cite this article as: Burcu M, Zito JM, Safer DJ, Magder LS, dosReis S, Shaya FT, Rosenthal GL, Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus, *Journal of the American Academy of Child & Adolescent Psychiatry* (2017), doi: 10.1016/j.jaac.2017.04.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus

RH: Concomitant AAP Use and Diabetes Risk

Mehmet Burcu, PhD, MS; Julie M. Zito, PhD; Daniel J. Safer, MD; Laurence S. Magder, PhD; Susan dosReis, PhD; Fadia T. Shaya, PhD, MPH; Geoffrey L. Rosenthal, MD, PhD

This article is discussed in an editorial by Dr. Christoph U. Correll on p. xx.

Supplemental material cited in this article is available online.

Accepted May 1, 2017

Drs. Burcu, Zito, Magder, dosReis, Shaya, and Rosenthal are with University of Maryland, Baltimore.

Dr. Safer is with Johns Hopkins Medical Institutions, Baltimore.

The study was supported, in part, by the University of Maryland, Baltimore and, in part, by a grant from the US Food and Drug Administration (1U01FD004320). The supporting organizations had no role in the design, conduct, or reporting of the study. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views and opinions of the supporting organizations.

The preliminary findings from this study were presented at the 2016 Mid-Year Meeting of the International Society for Pharmacoepidemiology, Baltimore, MD, April 10-12, 2016. This study is also a part of Dr. Burcu's doctoral dissertation.

Drs. Burcu and Magder served as the statistical experts for this research.

Disclosure: Drs. Burcu, Zito, Safer, Magder, dosReis, Shaya, and Rosenthal report no biomedical financial interests or potential conflicts of interest.

Correspondence to Mehmet Burcu, PhD, MS, Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, 220 Arch Street, Baltimore, MD 21201; email:

mburc001@umaryland.edu.

Download English Version:

<https://daneshyari.com/en/article/4931408>

Download Persian Version:

<https://daneshyari.com/article/4931408>

[Daneshyari.com](https://daneshyari.com)